Repository logo
 
Publication

Clinical Presentation and Long-Term Outcomes of Systemic Sclerosis Portuguese Patients from a Single Centre Cohort: A EUSTAR Registration Initiative

dc.contributor.authorVidal, C
dc.contributor.authorRuano, C
dc.contributor.authorBernardino, V
dc.contributor.authorLavado Carreira, P
dc.contributor.authorLladó, A
dc.contributor.authorSantos, MC
dc.contributor.authorGruner, H
dc.contributor.authorPanarra, A
dc.contributor.authorRiso, N
dc.contributor.authorMoraes-Fontes, MF
dc.date.accessioned2018-08-24T15:04:45Z
dc.date.available2018-08-24T15:04:45Z
dc.date.issued2018-06-29
dc.description.abstractINTRODUCTION: Systemic sclerosis is a complex disorder that requires systematic screening. Our objective is to report the European Scleroderma Trials and Research group centre affiliation and its impact in our clinical practice. MATERIAL AND METHODS: The European Scleroderma Trials and Research group affiliation process, database update and current patient evaluation, with respect to demographic and clinical features. Cumulative mortality was analysed. RESULTS: We identified 19 female patients (which met all the American College of Rheumatology/ European League Against Rheumatism 2013 criteria for systemic sclerosis) under current follow-up, divided according to the LeRoy classification into diffuse cutaneous (n = 5), limited cutaneous (n = 11) and limited (n = 3) types, followed for a median period of 5, 12 and 6 years, respectively. Raynaud´s phenomenon and abnormal nailfold capillaries were universally present. Interstitial lung disease was absent in the limited cutaneous form but present in 100% of the diffuse subtype. Pitting scars were more common in the diffuse form. Active disease was also more frequent in the diffuse form, and most patients with active disease were treated with anti-endothelin receptor antagonists. Over 21 years (from 1994 to 2015) the mortality rate was 55% (n = 23/42). Age at time of death was significantly lower in the diffuse subtype. DISCUSSION: Our single centre cohort shares many features with larger and international reports and more specifically is in accordance with patient characteristics described in the European Scleroderma Trials and Research group registries. CONCLUSION: The European Scleroderma Trials and Research group registration motivated our systematic patient characterization and may be used as a tool for homogenous disease registries.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationActa Med Port. 2018 Jun 29;31(6):312-320.pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/3038
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherOrdem dos Médicospt_PT
dc.subjectHSM IMApt_PT
dc.subjectHCC MEDpt_PT
dc.subjectEuropept_PT
dc.subjectRegistriespt_PT
dc.subjectScleroderma, Systemic/diagnosispt_PT
dc.subjectScleroderma, Systemic/mortality
dc.subjectScleroderma, Systemic/therapy
dc.subjectSurvival Rate
dc.subjectTime Factors
dc.subjectTreatment Outcome
dc.titleClinical Presentation and Long-Term Outcomes of Systemic Sclerosis Portuguese Patients from a Single Centre Cohort: A EUSTAR Registration Initiativept_PT
dc.title.alternativeEstudo Monocêntrico da Apresentação Clínica e Prognóstico a Longo Prazo de Doentes Portugueses com Esclerose Sistémica: uma Iniciativa do Registo EUSTARpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage320pt_PT
oaire.citation.issue6pt_PT
oaire.citation.startPage312pt_PT
oaire.citation.titleActa Médica Portuguesapt_PT
oaire.citation.volume31pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Acta Med Port 2018 312.pdf
Size:
326.4 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: